News | January 13, 2010

Funding for Transcatheter Valve Startup Paves Way for First-in-Man Study

January 13, 2010 – Transcatheter heart valve development company CardiAQ Valve Technologies (CVT) closed a $6.5 million funding deal to clinically validate its technology and carry the company through initial first-in-man studies.

The company is developing a self-conforming, self-anchoring technology for its Transcatheter Mitral Valve Implantation (TMVI) system. The device is designed to treat functional mitral regurgitation (FMR) in patients who are often too sick to have surgery. The company hopes to show in trials it nonsurgical alternative could be more effective than surgical replacement.

Through the combination of a specialized anchoring mechanism and a new delivery catheter, CVT said its device will enable physicians to accurately and securely implant a new mitral valve within a beating heart. The CVT procedure is designed for use in a cardiac catheterization laboratory, resulting in less trauma to the patient and substantial cost-savings to the healthcare system.

The funding was led by Rob Michiels and the same group of investors who were the first to recognize the potential of percutaneous aortic valve replacement with their 2002 investment in CoreValve.

For more information: www.cardiaq.com

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init